Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Labrie

Showing results (571-580 of 723) with videos related to

Pageof 73
Sort By:
Endocrinology|September 1, 1990
Localization of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase in rat gonads and adrenal glands by immunocytochemistry and in situ hybridizationE Dupont, H F Zhao, E Rhéaume, et al.
Bioorganic & Medicinal Chemistry|July 31, 1999
Spironolactone-related inhibitors of type II 17beta-hydroxysteroid dehydrogenase: chemical synthesis, receptor binding affinities, and proliferative/antiproliferative activitiesM R Tremblay, V Luu-The, G Leblanc, et al.
Urology|March 30, 1999
Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapyT H van der Kwast, B Têtu, B Candas, et al.
The Journal of Biological Chemistry|September 15, 1993
Structure and tissue-specific expression of a novel member of the rat 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD) family. The exclusive 3 beta-HSD gene expression in the skinJ Simard, J Couet, F Durocher, et al.
Nature Structural Biology|August 1, 1996
Crystal structure of human estrogenic 17 beta-hydroxysteroid dehydrogenase complexed with 17 beta-estradiolA Azzi, P H Rehse, D W Zhu, et al.
The American Journal of Surgical Pathology|February 1, 1991
Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical studyB Têtu, J R Srigley, J C Boivin, et al.
Journal of Steroid Biochemistry|November 1, 1989
Reversible inhibition of testicular androgen secretion by 3-, 5- and 6-month controlled-release microsphere formulations of the LH-RH agonist [D-Trp6, des-Gly-NH10(2)] LH-RH ethylamide in the dogD Lacoste, F Labrie, D Dubé, et al.
International Journal of Cancer|November 14, 1997
Comparative effects of 28-day treatment with the new anti-estrogen EM-800 and tamoxifen on estrogen-sensitive parameters in intact miceS Luo, C Martel, A Sourla, et al.
Journal of Steroid Biochemistry|November 1, 1986
Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancerF Labrie, A Dupont, M Giguere, et al.
Metabolism: Clinical and Experimental|March 1, 1987
Increase in plasma high-density lipoprotein concentration following complete androgen blockage in men with prostatic carcinomaS Moorjani, A Dupont, F Labrie, et al.
Pageof 73

Showing results (571-580 of 723) with videos related to

Sort By:
Pageof 73
Endocrinology|September 1, 1990
Localization of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase in rat gonads and adrenal glands by immunocytochemistry and in situ hybridizationE Dupont, H F Zhao, E Rhéaume, et al.
Bioorganic & Medicinal Chemistry|July 31, 1999
Spironolactone-related inhibitors of type II 17beta-hydroxysteroid dehydrogenase: chemical synthesis, receptor binding affinities, and proliferative/antiproliferative activitiesM R Tremblay, V Luu-The, G Leblanc, et al.
Urology|March 30, 1999
Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapyT H van der Kwast, B Têtu, B Candas, et al.
The Journal of Biological Chemistry|September 15, 1993
Structure and tissue-specific expression of a novel member of the rat 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD) family. The exclusive 3 beta-HSD gene expression in the skinJ Simard, J Couet, F Durocher, et al.
Nature Structural Biology|August 1, 1996
Crystal structure of human estrogenic 17 beta-hydroxysteroid dehydrogenase complexed with 17 beta-estradiolA Azzi, P H Rehse, D W Zhu, et al.
The American Journal of Surgical Pathology|February 1, 1991
Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical studyB Têtu, J R Srigley, J C Boivin, et al.
Journal of Steroid Biochemistry|November 1, 1989
Reversible inhibition of testicular androgen secretion by 3-, 5- and 6-month controlled-release microsphere formulations of the LH-RH agonist [D-Trp6, des-Gly-NH10(2)] LH-RH ethylamide in the dogD Lacoste, F Labrie, D Dubé, et al.
International Journal of Cancer|November 14, 1997
Comparative effects of 28-day treatment with the new anti-estrogen EM-800 and tamoxifen on estrogen-sensitive parameters in intact miceS Luo, C Martel, A Sourla, et al.
Journal of Steroid Biochemistry|November 1, 1986
Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancerF Labrie, A Dupont, M Giguere, et al.
Metabolism: Clinical and Experimental|March 1, 1987
Increase in plasma high-density lipoprotein concentration following complete androgen blockage in men with prostatic carcinomaS Moorjani, A Dupont, F Labrie, et al.
Pageof 73